Prospective studies in PTL
| Reference . | Year . | No. of patients . | Median age, years . | Range . | DLBCL (%) . | Treatment . | CNS prophylaxis . | Prognostic factors . | No. of patients with CNS relapse (%) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| 70 | 2002 | 16 | 62 | 29-73 | 100 | Age 18-60 y: VCAP | IT MTX all | N/R | 1 (6) | 6-y OS, 65% |
| Age 61-75 y: VECP-bleo | ||||||||||
| Regional RT | ||||||||||
| 71 | 2009 | 38 | 51.8 | 53-70 | 100 | R-CEOP 14 | MTX 6 g/m2 IV × 4 | N/R | (0) | 5-y EFS, 70% |
| 59 | 2011 | 56 | 64 | 22-79 | 100 | R-CHOP 21 | IT MTX × 4 | N/R | (6) | 5-y PFS, 74% |
| 5-y OS, 85% |
| Reference . | Year . | No. of patients . | Median age, years . | Range . | DLBCL (%) . | Treatment . | CNS prophylaxis . | Prognostic factors . | No. of patients with CNS relapse (%) . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|
| 70 | 2002 | 16 | 62 | 29-73 | 100 | Age 18-60 y: VCAP | IT MTX all | N/R | 1 (6) | 6-y OS, 65% |
| Age 61-75 y: VECP-bleo | ||||||||||
| Regional RT | ||||||||||
| 71 | 2009 | 38 | 51.8 | 53-70 | 100 | R-CEOP 14 | MTX 6 g/m2 IV × 4 | N/R | (0) | 5-y EFS, 70% |
| 59 | 2011 | 56 | 64 | 22-79 | 100 | R-CHOP 21 | IT MTX × 4 | N/R | (6) | 5-y PFS, 74% |
| 5-y OS, 85% |
EFS, event-free survival; IT, intrathecal; MTX, methotrexate; N/R, not reported; VCAP, vindesine, doxorubicin, cyclophosphamide, prednisolone; VECP-bleo, vindesine, epirubicin, cyclophosphamide, prednisolone, bleomycin. Additional abbreviations are explained in Table 2.